ID   Karpas-299
AC   CVCL_1324
SY   KARPAS-299; Karpas 299; KARPAS 299; Karpas299; KARPAS299; K299
DR   BTO; BTO:0002829
DR   CLO; CLO_0007065
DR   EFO; EFO_0005390
DR   CLDB; cl2995
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   BioGRID_ORCS_Cell_line; 624
DR   BioSample; SAMN03473348
DR   BioSample; SAMN10988031
DR   cancercelllines; CVCL_1324
DR   Cell_Model_Passport; SIDM01010
DR   ChEMBL-Cells; CHEMBL3308327
DR   ChEMBL-Targets; CHEMBL2366156
DR   Cosmic; 850199
DR   Cosmic; 907273
DR   Cosmic; 1086364
DR   Cosmic; 1086752
DR   Cosmic; 1509203
DR   Cosmic; 1995466
DR   Cosmic; 2674498
DR   Cosmic-CLP; 907273
DR   DepMap; ACH-000053
DR   DSMZ; ACC-31
DR   DSMZCellDive; ACC-31
DR   ECACC; 06072604
DR   EGA; EGAS00001000978
DR   GDSC; 907273
DR   GEO; GSM887195
DR   GEO; GSM888268
DR   GEO; GSM1217153
DR   GEO; GSM1669975
DR   IARC_TP53; 21427
DR   LiGeA; CCLE_563
DR   LINCS_LDP; LCL-1117
DR   Lonza; 18
DR   PharmacoDB; KARPAS299_729_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1324
DR   PubChem_Cell_line; CVCL_1324
DR   Wikidata; Q54899495
DR   Ximbio; 152418
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=3260522;
RX   PubMed=8558920;
RX   PubMed=9738977;
RX   PubMed=9787181;
RX   PubMed=11021758;
RX   PubMed=11494142;
RX   PubMed=15356658;
RX   PubMed=17170727;
RX   PubMed=20164919;
RX   PubMed=20922763;
RX   PubMed=22460905;
RX   PubMed=25355872;
RX   PubMed=26589293;
RX   PubMed=26657151;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=28356514;
RX   PubMed=29899875;
RX   PubMed=30285677;
RX   PubMed=30629668;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31978347;
RX   PubMed=35839778;
WW   http://www.cccells.org/cellreqs-ncipptp.php
WW   http://www.pptpinvitro.org/cell_lines_panel.php
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: MD Anderson Cell Lines Project.
CC   Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel.
CC   Population: Caucasian.
CC   Doubling time: 26 hours (PubMed=20922763); ~30 hours (ECACC=06072604).
CC   HLA typing: A*03:01,11:01; B*07:02,35:01; C*04:01,07:02; DQA1*01:02,01:02; DQB1*05:01,06:13; DRB1*01:01,15:01 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Gene fusion; HGNC; 427; ALK + HGNC; 7910; NPM1; Name(s)=NPM1-ALK (PubMed=26657151; PubMed=29899875).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Homozygous (Cosmic-CLP).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Omics: Virome analysis using RNAseq.
CC   Genome ancestry: African=0.22%; Native American=0.18%; East Asian, North=0%; East Asian, South=0%; South Asian=1.17%; European, North=67.06%; European, South=31.36% (PubMed=30894373).
CC   Misspelling: Karpass299; PubMed=28356514.
CC   Discontinued: DSMZ; ACC-31; true.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
ST   Source(s): Cosmic-CLP; COG; DSMZ; ECACC; PubMed=20922763
ST   Amelogenin: X,Y
ST   CSF1PO: 10,11
ST   D13S317: 8,12
ST   D16S539: 12
ST   D18S51: 16,18
ST   D19S433: 14,15.2 (COG; PubMed=20922763)
ST   D19S433: 14,16 (DSMZ)
ST   D21S11: 27,29
ST   D2S1338: 16,17
ST   D3S1358: 16,18
ST   D5S818: 11,12
ST   D7S820: 10,11
ST   D8S1179: 12
ST   FGA: 21,22
ST   Penta D: 10,14
ST   Penta E: 12,16
ST   TH01: 7,8.3 (COG; ECACC; PubMed=20922763)
ST   TH01: 7,9 (Cosmic-CLP; DSMZ)
ST   TPOX: 8
ST   vWA: 17,19
DI   NCIt; C37193; Anaplastic large cell lymphoma, ALK-positive
DI   ORDO; Orphanet_300895; ALK-positive anaplastic large cell lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   25Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 43
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=3260522; DOI=10.1182/blood.V72.1.234.234;
RA   Fischer P., Nacheva E., Mason D.Y., Sherrington P.D., Hoyle C.,
RA   Hayhoe F.G.J., Karpas A.;
RT   "A Ki-1 (CD30)-positive human cell line (Karpas 299) established from
RT   a high-grade non-Hodgkin's lymphoma, showing a 2;5 translocation and
RT   rearrangement of the T-cell receptor beta-chain gene.";
RL   Blood 72:234-240(1988).
//
RX   PubMed=8558920;
RA   Dirks W.G., Zaborski M., Jager K., Challier C., Shiota M.,
RA   Quentmeier H., Drexler H.G.;
RT   "The (2;5)(p23;q35) translocation in cell lines derived from malignant
RT   lymphomas: absence of t(2;5) in Hodgkin-analogous cell lines.";
RL   Leukemia 10:142-149(1996).
//
RX   PubMed=9738977; DOI=10.1111/j.1349-7006.1998.tb03275.x;
RA   Takizawa J., Suzuki R., Kuroda H., Utsunomiya A., Kagami Y., Joh T.,
RA   Aizawa Y., Ueda R., Seto M.;
RT   "Expression of the TCL1 gene at 14q32 in B-cell malignancies but not
RT   in adult T-cell leukemia.";
RL   Jpn. J. Cancer Res. 89:712-718(1998).
//
RX   PubMed=9787181; DOI=10.1182/blood.V92.9.3410;
RA   Sakai A., Thieblemont C., Wellmann A., Jaffe E.S., Raffeld M.;
RT   "PTEN gene alterations in lymphoid neoplasms.";
RL   Blood 92:3410-3415(1998).
//
RX   PubMed=11021758; DOI=10.1038/sj.leu.2401891;
RA   Majka M., Rozmyslowicz T., Honczarenko M., Ratajczak J., Wasik M.A.,
RA   Gaulton G.N., Ratajczak M.Z.;
RT   "Biological significance of the expression of HIV-related chemokine
RT   coreceptors (CCR5 and CXCR4) and their ligands by human hematopoietic
RT   cell lines.";
RL   Leukemia 14:1821-1832(2000).
//
RX   PubMed=11494142; DOI=10.1038/sj.onc.1204582;
RA   Turturro F., Frist A.Y., Arnold M.D., Seth P., Pulford K.;
RT   "Biochemical differences between SUDHL-1 and KARPAS 299 cells derived
RT   from t(2;5)-positive anaplastic large cell lymphoma are responsible
RT   for the different sensitivity to the antiproliferative effect of
RT   p27(Kip1).";
RL   Oncogene 20:4466-4475(2001).
//
RX   PubMed=15356658; DOI=10.1038/sj.leu.2403465;
RA   Drexler H.G., MacLeod R.A.F.;
RT   "Malignant hematopoietic cell lines: in vitro models for the study of
RT   anaplastic large-cell lymphoma.";
RL   Leukemia 18:1569-1571(2004).
//
RX   PubMed=17170727; DOI=10.1038/sj.leu.2404486;
RA   Sandberg Y., Verhaaf B., van Gastel-Mol E.J., Wolvers-Tettero I.L.M.,
RA   de Vos J., MacLeod R.A.F., Noordzij J.G., Dik W.A., van Dongen J.J.M.,
RA   Langerak A.W.;
RT   "Human T-cell lines with well-defined T-cell receptor gene
RT   rearrangements as controls for the BIOMED-2 multiplex polymerase chain
RT   reaction tubes.";
RL   Leukemia 21:230-237(2007).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20922763; DOI=10.1002/pbc.22801;
RA   Kang M.H., Smith M.A., Morton C.L., Keshelava N., Houghton P.J.,
RA   Reynolds C.P.;
RT   "National Cancer Institute pediatric preclinical testing program:
RT   model description for in vitro cytotoxicity testing.";
RL   Pediatr. Blood Cancer 56:239-249(2011).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=25355872; DOI=10.1128/JVI.02570-14;
RA   Cao S.-B., Strong M.J., Wang X., Moss W.N., Concha M., Lin Z.,
RA   O'Grady T., Baddoo M., Fewell C., Renne R., Flemington E.K.;
RT   "High-throughput RNA sequencing-based virome analysis of 50 lymphoma
RT   cell lines from the Cancer Cell Line Encyclopedia project.";
RL   J. Virol. 89:713-729(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=26657151; DOI=10.1038/onc.2015.456;
RA   Ceccon M., Merlo M.E.B., Mologni L., Poggio T., Varesio L.M.,
RA   Menotti M., Bombelli S., Rigolio R., Manazza A.D., Di Giacomo F.,
RA   Ambrogio C., Giudici G., Casati C., Mastini C., Compagno M.,
RA   Turner S.D., Gambacorti-Passerini C., Chiarle R., Voena C.;
RT   "Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and
RT   drug dependency.";
RL   Oncogene 35:3854-3865(2016).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=28356514; DOI=10.1073/pnas.1700682114;
RA   Chen J., Zhang Y., Petrus M.N., Xiao W.-M., Nicolae A., Raffeld M.,
RA   Pittaluga S., Bamford R.N., Nakagawa M., Ouyang S.T.-Y., Epstein A.L.,
RA   Kadin M.E., Del Mistro A., Woessner R.D., Jaffe E.S., Waldmann T.A.;
RT   "Cytokine receptor signaling is required for the survival of ALK-
RT   anaplastic large cell lymphoma, even in the presence of JAK1/STAT3
RT   mutations.";
RL   Proc. Natl. Acad. Sci. U.S.A. 114:3975-3980(2017).
//
RX   PubMed=29899875; DOI=10.18632/oncotarget.25489;
RA   Krumbholz M., Woessmann W., Zierk J., Seniuk D., Ceppi P.,
RA   Zimmermann M., Singh V.K., Metzler M., Damm-Welk C.;
RT   "Characterization and diagnostic application of genomic NPM-ALK fusion
RT   sequences in anaplastic large-cell lymphoma.";
RL   Oncotarget 9:26543-26555(2018).
//
RX   PubMed=30285677; DOI=10.1186/s12885-018-4840-5;
RA   Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X.,
RA   Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H.,
RA   Koeffler H.P.;
RT   "Profiling the B/T cell receptor repertoire of lymphocyte derived cell
RT   lines.";
RL   BMC Cancer 18:940.1-940.13(2018).
//
RX   PubMed=30629668; DOI=10.1371/journal.pone.0210404;
RA   Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.;
RT   "Screening human cell lines for viral infections applying RNA-Seq data
RT   analysis.";
RL   PLoS ONE 14:E0210404-E0210404(2019).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//